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Sirtuins family
The sirtuins, silent mating-type information regulation 2 (SIRTs), are a family of nicotinamide adenine dinucleotide (NAD + )-dependent histone deacetylases. SIRTs are activated in response to low cellular energy stores and have been implicated in the control of many physiological processes including senescence (1) . The life-prolonging effects of SIRTs were first described in Saccharomyces cerevisiae (2) .
The regulation of SIRTs by NAD + dictates that the activity of these enzymes alters in response to changes in prevailing intracellular redox potential (1) and SIRTs have been found to have important roles in energy regulation (3) . The main chemical reactions catalyzed by sirtuin enzymes are protein lysine deacetylations. Sirtuins couple the deacetylation of lysine to the hydrolysis of NAD+ by transferring the acetyl group to the adenosine diphosphate (ADP)-ribose moiety to form O-acetyl-ADP-ribose, releasing free nicotinamide (4) . Seven closely-related SIRT family members have been identified and these are divided into four classes: class I (consisting of SIRT1, SIRT2, and SIRT3), class II (SIRT4), class III (SIRT5), and class IV (SIRT6 and SIRT7) (5, 6) . The SIRTs have a conserved core catalytic domain, but they differ with respect to their distribution in tissues and their intracellular locations (7) . SIRT1, SIRT6
and SIRT7 are predominantly located in the nucleus, SIRT2 is unique in its cytoplasmic location, and SIRT3, SIRT4 and SIRT5 are mitochondrial SIRTs (8) . Of the seven SIRT subtypes, SIRT1, SIRT3, and SIRT6 have been most extensively characterized and are the focus of this narrative review.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
factors (FOXOs), nuclear factor κB (NF-κB), tumor protein 53 (p53), peroxisome proliferator-activated receptor-γ co-activator-1α (PGC-1α), and several DNA damage repair proteins including Ku70 (11) (12) (13) (14) .
SIRT1 deficiency contributes to increased inflammation, oxidative stress, foam cell formation, impaired nitric oxide (NO) production and autophagy, thereby promoting vascular aging and atherosclerosis (11- 14).
SIRT3
SIRT3 regulates several mitochondrial functions and it has important roles in maintaining homeostasis, particularly under conditions of stress (15) . However, SIRT3 does not appear to be a prerequisite for life, as demonstrated by knockout mice models which showed an almost normal phenotype at birth -although these animals displayed excessive acetylation of mitochondrial proteins (16) . SIRT3 participates in the control of fatty-acid metabolism, and SIRT3 knockout mice demonstrate abnormal lipid metabolism which is associated with abnormal accumulation of acylcarnitines and triglycerides in the livers of these animals during fasting (17) . Multiple cellular targets including manganese-dependent superoxide dismutase (MnSOD), NADH dehydrogenase sub-complex 9, and succinate dehydrogenase complex subunit A have been identified as being modulated by SIRT3 (18, 19) . SIRT3 provides protection against oxidative stress by deacetylation and activation of superoxide dismutase 2 (20) . Roos et al. indicated that loss of SIRT3 does not change endothelial function in advanced atherosclerosis, but may lead to augmentation of osteogenic signaling and accelerated progression of vascular calcification (21).
SIRT6
The core domain of SIRT6 is flanked by a N-terminal which is necessary for histone deacetylation and chromatin association and a C-terminal which is required for the nuclear localization of this SIRT subtype (22). Primarily characterized as an NAD+-dependent histone deacetylase (23) , SIRT6 targets the histones H3K9 (10) and H3K56 (24) and also directly deacetylases a variety of proteins (24, 25) . SIRT6 expression M A N U S C R I P T
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is decreased in atherosclerotic lesions from ApoE−/− mice (26) and human patients (27). However, the role of SIRT6 in regulating vascular endothelial function and atherosclerosis is not well understood.
Recently Xu et al. reported that SIRT6 reduces the formation of atherosclerotic lesions via the attenuation of endothelial dysfunction and vascular inflammation (28) .
Putative therapeutic roles of SIRTs
SIRTs regulate a variety of genes which encode proteins that regulate inflammation and endothelial cell function (10) . 
Atherosclerosis
Atherosclerosis is a progressive disorder, which develops from foam cells and fatty streaks in arterial walls through several stages of development, ultimately resulting in atherosclerotic plaques. The plaques can obstruct blood flow. In the coronary circulation this can result in symptoms of angina pectoris. If the plaques rupture, they expose the platelets to pro-aggregatory stimuli leading to thrombogenesis and its sequelae: coronary thrombosis and myocardial infarction. A similar process in cerebral arteries results in M A N U S C R I P T
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ischaemic stroke (35) . Research in recent decades has increasingly highlighted the roles of oxidative stress, inflammation (36) (37) (38) , macrophage infiltration and deposition of oxidized low-density lipoprotein (ox-LDL) cholesterol in the walls of blood vessels and endothelial dysfunction in the pathophysiology of atherosclerosis (35, 39) . Results from preclinical studies suggest that SIRTs are involved in the regulation of many of these pathways. This review focuses on the vascular biology of SIRT1, SIRT3 and SIRT6, with a focus on the roles of these enzymes and their modulators on biological molecules and processes involved in atherogenesis, including lipid metabolism, inflammation and endothelial function.
Potential for SIRTs to modulate factors involved in the development atherosclerosis
Lipid modification
The deposition of oxidized lipids in arterial walls is a characteristic of atherosclerosis (35, 39) . 
Reduction of oxidative stress
Anti-atherosclerotic actions of SIRTs may derive from their potential to reduce the severity of oxidative stress and stress-induced endothelial injury (52) (53) . SIRT1 exerts antioxidant effects by modulating FOXO signaling (54) . FOXO proteins have many functions, including cell cycle, metabolism, apoptosis,
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stress resistance, DNA repair, and aging (55) . Deacetylation and then activation of FOXO1, 3 and 4 transcription factors by SIRT1 reduces oxidative stress by induction of anti-oxidative enzymes in endothelial cells (56) . SIRT1 promotes the expression of FOXO target genes associated with stress resistance, and decreases the transcription of genes associated with apoptosis (57) . Genetic variations at the SIRT1 and FOXO1 loci have been found to be associated with carotid atherosclerosis. A pronounced effect was found for two SNPs (rs10507486 and rs2297627) at FOXO1 and common carotid intima-media thickness (58) . SIRT1 has been shown to promote the ubiquitination and degradation of FOXO3a, which protects endothelial progenitor cells against oxidative stress-induced apoptosis (59).
SIRT3 reduces intracellular activity of reactive oxygen species (ROS) via deacetylation and stimulation of mitochondrial superoxide dismutase 2 (SOD2) (19) , an enzyme responsible for the conversion of superoxide to molecular oxygen or hydrogen peroxide. (53) . Correspondingly, it has been demonstrated that SIRT3 deficiency in murine and human pulmonary artery smooth muscle cells was associated with induction of the transcription factors involved in the pathogenesis of pulmonary artery hypertension hypoxia-inducible factor 1A (HIF1A), signal transducer and activator of transcription-3 (STAT3), and nuclear factor of activated T cells 2 (NFATc2) (60) . Moreover, SIRT3 deficiency induces a mild, superoxide-dependent endothelial dysfunction in mice fed a high-cholesterol diet (61).
Anti-inflammatory actions
SIRTs have the potential to reduce the inflammatory component of atherosclerotic disease. In particular this may occur through regulation of nuclear factor-kB (NF-kB), which regulates the expression of cytokines, chemokines and other pro-inflammatory agents (62).
SIRT6 is an important regulator of inflammation. In endothelial cells, the down regulation of SIRT6 is associated with enhanced expression of NF-kB, while overexpression of SIRT6 is associated with diminished NF-kB activity. SIRT6 thus appears to modulate the up-regulation of genes involved in M A N U S C R I P T
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inflammation, vascular remodelling, oxidative stress and angiogenesis including interleukin1β (IL-1β)
.
In a murine model, haploinsufficiency of SIRT6 results in more rapid atherosclerotic plaque formation and greater carotid plaque instability than in homozygous SIRT6 controls. The homozygote animals had greater expression of inflammatory cytokines (63) . Interestingly, the study also found that expression of SIRT6 was lower in carotid arteries from patients with atherosclerotic disease, compared to normal controls (63)
Macrophage migration and foam cell deposition
Uptake of ox-LDL into endothelial cells, an important stage in the development of atherosclerosis, is achieved via several scavenger receptors, for example lectin-like oxidized low-density lipoprotein receptor-1 (Lox-1) and CD36 (64) . Inhibition of Lox-1 expression would appear to be a potential therapeutic strategy against atherosclerosis (65) . SIRT1 reduces the expression of the scavenger receptor Lox-1 in macrophages (66) , and may thereby act to slow the development of foam cells. Reduction of Lox-1 expression by SIRT1 is associated with suppression of NF-signaling by deacetylation of RelA/p65 (66) . SIRT1 also exerts CD36 dependent and independent activities related to ox-LDL uptake (57).
Moreover, it was also indicated that SIRT1 does not affect scavenger receptor class B type I (SR-B1) which mediates cellular HDL cholesterol uptake (44). In addition, SIRT1 may stabilize existing atherosclerotic plaques by enhancing the activity of tissue inhibitor of metalloproteinase 3 in vascular smooth muscle cells (67).
Autophagy
Autophagy is catabolic process through which damaged organelles and macromolecules are degraded and 
Vascular function
Two recent studies conducted in mouse models have investigated the effects of SIRT6 upon vascular function using similar methods (26, 28). Endothelial derived relaxation, provoked by an acetylcholine challenge, was impaired in haploinsufficient SIRT6 +/-mice (28) and when the function of SIRT6 was attenuated by small hairpin RNAs. Haploinsufficiency SIRT6 +/-mice had increased rates of atherogenesis associated with elevated vascular cell adhesion molecule-1 (VCAM-1), an inflammatory cytokine.
Correspondingly, SIRT6 overexpression was associated with reduced expression of pro-atherosclerotic genes (including tumour necrosis factor (TNF) family members and reduced adhesion of monocytes to endothelial cells) (28) M A N U S C R I P T
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SIRTs and cigarette smoke
Cigarette smoke causes generalized endothelial dysfunction (75, 76) , which is usually an indicator of an increased oxidative stress. In smokers and in subjects with diabetes, SIRT1 expression and/or activity may be decreased, despite the fact that the protective effects of SIRT1 against oxidative stress would be especially helpful in this situation. It was found that the SIRT1 activator SRT2104 is safe and well 
SIRTs and statins
In addition to their well-documented lipid-modifying effects, statins (3-hydroxy-3-methylglutaryl- 
Metformin
Metformin is a safe and widely used antidiabetic drug. In addition to its well-characterized reductions in plasma glucose, it has anti-inflammatory properties with the potential to modulate important components of the pathophysiology of atherosclerosis. (88, 89) . Metformin increases SIRT1 expression and activity
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and represses the expression of inflammatory markers such as I1-6 and TNF-alpha in patients with carotid artery atherosclerosis (90) . Metformin has been shown to promote phosphorylation of 5' adenosine monophosphate-activated protein kinase (AMPK), which leads to protection against oxidative injuries (91) . The signaling pathways of metformin-mediated anti-atherosclerotic effects involve inhibition of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity and the ROS formation, which impair the LOX-1 up-regulation and AKT/eNOS deactivation. Importantly, these protective mechanisms are attenuated when SIRT1 and AMPK are repressed (92).
Resveratrol
Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is a polyphenol found in natural products including grapes (93) . Resveratrol is a strong activator of SIRT1 and it is potentially anti-atherosclerotic (2, 94, 95).
Disappointingly, a well-conducted and extensive meta-analysis did not find any evidence of resveratrol supplementation impacting plasma lipids, or other risk factors (96).
Genistein
Genistein (4',5,7-trihydroxyisoflavone) is an isoflavone which is present mainly in soybeans and red clover. It has anti-atherosclerotic activities (97) (98) (99) . Genistein increases the activity of endothelial nitric oxide synthase (eNOS) and the production of nitric oxide (NO) (100) . NO is a vasodilator and reduced endothelial NO production is a hallmark of endothelial dysfunction and atherosclerosis. In human umbilical vein endothelial cells (HUVECs), genistein has been shown to reverse eNOS uncoupling induced by ox-LDL, a process modulated by a SIRT1-dependent pathway (100). This observation provides an important potential mechanism for the anti-atherosclerotic actions of genistein and SIRT activators in general.
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Quercetin
Quercetin is a flavonoid with anti-oxidative and anti-inflammatory activities. It is present in vegetables, fruits, herbs and red wine (101) . Like genistein, quercetin suppresses ox-LDL-induced endothelial dysfunction by activating SIRT1 (102).
Berberine
Berberine is a botanical alkaloid mainly isolated from the Chinese herb Coptis chinensis which has been proposed as an anti-atherosclerotic agent (103) . In a cell-culture model, berberine has been shown to reduce the formation of foam cell formation by activating the AMPK-Sirt1-PPAR-γ pathway and by reduction of the uptake of ox-LDL by monocytes (104).
Curcumin
Curcumin is a polyphenol extract of Curcuma longa. Curcumin enhances cholesterol efflux from macrophages, an important step in reverse cholesterol transport, whereby cholesterol is returned to the liver for metabolism. This effect of curcumin may result from an increase of ABCA1 expression through activation of AMPK-Sirt1-LXRα signaling in THP-1 macrophage-derived foam cells (105) . Such effects may reduce the development of atherosclerosis and indeed curcumin has been proposed as an antiatherosclerotic agent (106).
Delphinidin-3-glucoside
Delphinidin-3-glucoside is a natural anthocyanin which is found in a variety of fruits, vegetables, and cereals (107) . Several studies have demonstrated potentially beneficial effects of anthocyanins on atherosclerosis, but the mechanisms have not been fully elucidated (108) . It has been shown that M A N U S C R I P T
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delphinidin-3-glucoside protects against ox-LDL-induced injury in HUVECs (108) . This effect may be mediated via an adenosine monophosphate-activated protein kinase/Sirt1 signaling pathway (109).
Ginkgolide B
Ginkgolide B is an extract of the ginkgo leaf and is a natural inhibitor with potentially protective effects on endothelial cells (110) Ginkgolide B can protect against endothelial cell injury by reducing LOX-1 and increasing Sirt1 (111) and it has been suggested as a potential agent for the prevention of atherosclerosis (111, 112) .
Evaluation of clinical effects of pharmacological modulators of SIRTs
The compounds described above have shown promise in varying degrees in the modulation of SIRT function. More rigorous evaluation of these compounds is needed before any recommendations can be made with respect to their clinical use. Metformin is probably the most promising candidate in this respect, because its widespread availability as a pharmaceutical preparation would make a large randomised controlled trial realatively easy to facilitate (88) (89) (90) (91) (92) . Such a trial could be used to measure the effect of the drug on SIRT function and clinical outcomes, to determine whether these effects were correlated with one another. Natural products such as resveratrol, genistein, quercetin, berberine, curcumin, delphinidin-3-glucoside and ginkgolide B may be harder to investigate robustly owing to difficulties in measuring dietary intake in observational studies and because of the difficulty in eliminating variability between batches of supplements used in controlled studies (94) (95) (96) (97) (98) (99) (100) (101) (102) (103) (104) (105) (106) (107) (108) (109) (110) (111) (112) . Perhaps the most practical approach to further research would be to investigate metformin initially as a 'proof of concept' and then to investigate natural products if studies with metformin suggested a SIRT-mediated benefit of metformin.
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Conclusions
SIRTs appear to have a prominent role in vascular biology, and in preclinical models they promote a variety of physiological effects, which would be expected to oppose atherogenesis. Preclinical studies suggest roles for SIRTs in protecting vascular smooth muscle and endothelial cells from the deleterious effects associated with lipid deposition, oxidative stress, and inflammation. Although clinical data are currently limited, and caution must be applied when extrapolating from the results of preclinical studies, the availability and safety of SIRT activators such as metformin and resveratrol make possible the studies that will be necessary to better understand the role of SIRTs in human atherosclerosis. These encouraging observations necessitate rigorous large clinical trials to determine the roles of SIRT activators on cardiac outcomes such as incident myocardial infarction and mortality.
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HIGHLIGHTS:
• The sirtuins, silent mating-type information regulation 2 (SIRTs), are a family of nicotinamide adenine dinucleotide (NAD + )-dependent histone deacetylases
• SIRTS have important roles in regulating energy metabolism and senescence.
• Activation of SIRTs appears to have beneficial effects on lipid metabolism and antioxidants
• The availability and safety of SIRT activators such as metformin and resveratrol provide an excellent opportunity to conduct research to better understand the role of SIRTs in human atherosclerosis.
